Finnish health technology company Netmedi has developed a digital platform, Kaiku Health IO, for the follow-up of patients treated with immune checkpoint inhibitors.
The solution is about to enter multi-center clinical validation phase and has attracted interest among a number of oncology clinics. The platform provides a solution for enhanced management of immune-related adverse events, supporting patients and the care team throughout treatment and follow-up. Netmedi will launch it at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 4.
Kaiku Health IO monitors the health status of patients in real-time and collects structured information about the impact of immunotherapy. The platform enables the care team to treat patients more effectively according to their individual needs, and to react timely to any alarming signals during treatment and recovery.
“Cancer immunotherapy has the potential to significantly extend the lives of many cancer patients, which underlines the importance of systematic patient follow-up,” says Professor Paolo A. Ascierto, Director at National Tumor Institute Fondazione G. Pascale, Naples, Italy. “In addition, the adverse event profile of immunotherapy differs from conventional oncological treatments. These events can be better managed if they are detected and treated early on. Immunotherapy sets new requirements for patient follow-up”.
The institute headed by Professor Ascierto has extensive experience in treating patients with immune checkpoint inhibitors. Kaiku Health IO was developed in cooperation with several Finnish and European oncology experts.